Jerrold B. Grossman Buys 10,200 Shares of ADMA Biologics Inc (NASDAQ:ADMA) Stock

ADMA Biologics Inc (NASDAQ:ADMA) Director Jerrold B. Grossman bought 10,200 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were bought at an average cost of $2.89 per share, for a total transaction of $29,478.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

NASDAQ:ADMA opened at $3.12 on Friday. ADMA Biologics Inc has a 52 week low of $1.45 and a 52 week high of $5.48. The company has a quick ratio of 6.75, a current ratio of 11.10 and a debt-to-equity ratio of 1.29. The stock has a market capitalization of $262.49 million, a PE ratio of -3.63 and a beta of 2.12. The stock’s 50-day moving average price is $3.01 and its 200-day moving average price is $3.01.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.07). ADMA Biologics had a negative net margin of 164.90% and a negative return on equity of 104.32%. Sell-side analysts expect that ADMA Biologics Inc will post -0.77 earnings per share for the current fiscal year.

A number of equities analysts recently issued reports on ADMA shares. Oppenheimer started coverage on ADMA Biologics in a research note on Thursday, August 6th. They issued a “buy” rating and a $6.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of ADMA Biologics in a research note on Thursday, August 6th. Zacks Investment Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. Maxim Group assumed coverage on ADMA Biologics in a research note on Friday, May 22nd. They set a “buy” rating and a $6.00 price objective for the company. Finally, BidaskClub lowered ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. ADMA Biologics currently has an average rating of “Buy” and an average target price of $8.00.

Several large investors have recently bought and sold shares of ADMA. Goldman Sachs Group Inc. grew its position in shares of ADMA Biologics by 177.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 351,795 shares of the biotechnology company’s stock valued at $1,407,000 after acquiring an additional 225,126 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of ADMA Biologics by 20.9% during the 4th quarter. Bank of New York Mellon Corp now owns 161,653 shares of the biotechnology company’s stock worth $647,000 after purchasing an additional 27,901 shares during the last quarter. Geode Capital Management LLC raised its position in shares of ADMA Biologics by 15.1% during the 4th quarter. Geode Capital Management LLC now owns 716,608 shares of the biotechnology company’s stock valued at $2,866,000 after buying an additional 94,114 shares during the period. Nuveen Asset Management LLC raised its position in shares of ADMA Biologics by 108.3% during the 4th quarter. Nuveen Asset Management LLC now owns 278,700 shares of the biotechnology company’s stock valued at $1,115,000 after buying an additional 144,913 shares during the period. Finally, Raymond James & Associates raised its position in shares of ADMA Biologics by 86.1% during the 1st quarter. Raymond James & Associates now owns 223,790 shares of the biotechnology company’s stock valued at $645,000 after buying an additional 103,545 shares during the period. Hedge funds and other institutional investors own 56.12% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: How Investors Can Profit from Options Trading

Insider Buying and Selling by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit